Please select the outcome measures that correspond to the clinical trial below.
Title: In-Person VS. Computer Interventions for Increasing Probation Compliance
Brief Summary: Substance abuse treatment in the criminal justice system can reduce drug use and related criminal behavior. Although drug and alcohol treatment are common mandates in criminal justice programs, only a minority of clients actually initiate treatment. This proposal will compare two intervention formats that target motivation to initiate and engage in treatment among a group of probationers who have drug or alcohol treatment conditions. Six hundred drug and alcohol offenders in two probation sites (Baltimore, MD and Dallas, TX) will be randomized to receive: 1) an in-person motivational interviewing session (MI), 2) a motivational computer program (MC), or 3) supervision intake and monitoring as usual (SAU). The MI condition will be structured along the lines of the "Check-Up" format which consists of an assessment and personalized feedback delivered in an MI style; the content of the MC condition will be drawn from previous literature on effective motivational computer programs. Both interventions will be delivered at the start of the probation process, with follow-up assessments at 2 and 6 months. Primary outcomes include engagement and participation in substance abuse treatment; secondary outcomes include drug and alcohol use, probation progress, criminal behavior, and HIV testing and care. This project will be the first to develop and test two interventions for encouraging criminal justice clients to follow through with treatment recommendations, with the goal of increasing treatment initiation, and reducing subsequent drug use and criminal behavior. It also contributes to ongoing partnerships with two large probation agencies-the Dallas County Supervision and Corrections Department and the Maryland Division of Parole and Probation.


Options:
A: Treatment Progress (6 months)
B: Rates of HIV Seroconversion (From date of randomization until the date of first documented seroconversion or date of death from any cause, whichever came first, assessed for an average of 4.0 years, with a maximum duration of 6.9 years); Renal Toxicity (Blood tested for creatinine level at enrollment and every 3 months, up to 6.9 years); Adverse Events (Up to 6.9 years)
C: N/A
D: CTCR Baseline & Follow-Up Protocol (CTCR Protocol) (Baseline and at 3, 6, 12, and 18 months); Colorado Department of Corrections Record Information System (CDOC-RIS) (At 6, 12, and 18 months); Biological Specimens (At 12 and 18 months); Diagnostic Interview Survey-IV (DIS-IV) (At baseline); Beck Depression Inventory-II (BDI-II) (At baseline and 3, 6, 12, and 18 months); Symptom Checklist 90-R (SCL90-R) (At baseline and 3, 6, 12, and 18 months); Rosenberg Self-Esteem (R-SES) (At baseline and 3, 6, 12, and 18 months); Measures of Social Network (adapted) (At baseline and 3, 6, 12, and 18 months); Client Assessment Inventory (CAI) & Staff Assessment Summary (SAS) (At 3 and 6 months); Therapeutic Community Scale of Essential Elements Questionnaire(SEEQ) (administered monthly over the first six months of the project and quarterly thereafter); Treatment Services Review (TSR) (administered monthly over the first six months of the project and quarterly thereafter); Program Monitoring Form (PMF) (administered monthly over the first six months of the project and quarterly thereafter)

Answer: A